The Center for Health Information and Analysis (CHIA) today released its second study on prescription drug use and spending in an effort to shine a light on the drivers of pharmacy expenditures, including high volume and high cost drugs.
To advance transparency in this area of the health care market for policymakers, researchers, and the public, CHIA has published an interactive dashboard
and detailed dataset, allowing users to see drivers of prescription drug spending as well as the associated conditions these drugs treat.
For this analysis, CHIA used a subset of commercial pharmacy claims from the agency's All Payer Claims Database (APCD) to identify high volume and high cost drugs between 2015 and 2017.
- Ten therapeutic classes of drugs, which include antivirals, antiasthmatics, cardiovascular, and psychotherapeutic drugs, accounted for over 70% of pharmacy expenditures.
- Anti-inflammatory TNF inhibiting agents, a class of drugs that includes Humira and Enbrel, accounted for the largest proportion of spending.
- The most frequently prescribed drug during the three year period was Lisinopril, an ACE inhibitor that treats high blood pressure and heart failure.